Results 41 to 50 of about 1,097,021 (302)
The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang +3 more
doaj +1 more source
Bub3p facilitates spindle checkpoint silencing in fission yeast [PDF]
Although critical for spindle checkpoint signaling, the role kinetochores play in anaphase promoting complex (APC) inhibition remains unclear. Here we show that spindle checkpoint proteins are severely depleted from unattached kinetochores in fission ...
Hardwick, Kevin G. +13 more
core +1 more source
The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina +13 more
doaj +1 more source
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera +1 more
doaj +1 more source
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon +3 more
doaj +1 more source
Cardio-toxicity of checkpoint inhibitors [PDF]
Immune checkpoint inhibitors (ICIs) have started revolutionizing the treatment of numerous advanced oncological diseases by restoring immune resistance against cancer cells. ICI-associated cardiac adverse effects are rare, but severe. About 50% of cardiac complications comprise myocarditis with variable clinical presentation and a high rate of fatality.
Oliver J, Müller +2 more
openaire +2 more sources
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Background We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF.
Fei Liang +3 more
doaj +1 more source
Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj +1 more source
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira +9 more
core +1 more source
Translational target for checkpoint inhibitors [PDF]
Eukaryotic translation initiation complex eIF4F is identified as an upstream regulator of PD-L1 expression and is therefore a promising target for immunotherapy.
openaire +2 more sources

